Premium
The use of bisphosphonates in cancer treatment
Author(s) -
Coleman Robert
Publication year - 2011
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2010.05766.x
Subject(s) - zoledronic acid , medicine , breast cancer , multiple myeloma , cancer , bone pain , bone disease , quality of life (healthcare) , disease , adjuvant , oncology , intensive care medicine , osteoporosis , nursing
Bone metastases result in considerable morbidity and exert complex demands on health care resources. Additionally, for many patients, metastatic bone disease is a chronic condition affecting quality of life and independence over years rather than months. The bisphosphonates, notably zoledronic acid, have been shown to reduce skeletal morbidity in multiple myeloma, as well as a wide range of solid tumors affecting bone, by 30–50%. Quite appropriately, the bisphosphonates are increasingly used alongside anticancer treatments to prevent skeletal complications and relieve bone pain. In addition, they are increasingly used to prevent cancer treatment–induced bone loss and show promise in the adjuvant setting to prevent metastasis from breast cancer.